Circulating free DNA concentration as a marker of disease recurrence and metastatic potential in lung cancer
Authors:
- Hanifeh Mirtavoos‐MahyariHMHanifeh Mirtavoos‐Mahyari
- Soudeh Ghafouri‐FardSGSoudeh Ghafouri‐Fard
- Adnan KhosraviAKAdnan Khosravi
- Elahe MotevaseliEMElahe Motevaseli
- Zahra Esfahani‐MonfaredZEZahra Esfahani‐Monfared
- Sharareh SeifiSSSharareh Seifi
- Babak SalimiBSBabak Salimi
- Vahid Kholghi OskooeiVOVahid Kholghi Oskooei
- Mohsen GhadamiMGMohsen Ghadami
- Mohammad Hossein ModarressiMMMohammad Hossein Modarressi
Open Access
- 18 April 2019
- journal article
- research article
- Published by Wiley in Clinical and Translational Medicine
- Vol. 8 (1) , 14
Abstract
Background: Plasma circulating cell‐free (cf) DNA is regarded as a source of tumor DNA. Based on availability of blood tissue for the purposes of early detection of cancer and patients’ follow‐up, several studies have evaluated concentration of cf DNA in cancer patients in association with tumor features. In the present study, we assessed concentration of cf DNA in lung cancer patients with two commercial kits (MN and QIAGEN) to find whether it can be used as a prognostic biomarker.Results: Primary cf DNA concentrations as measured by QIAGEN kit was significantly higher in patients who died in the follow‐up period compared with alive patients (P = 0.007). Moreover, the concentrations as measured by both methods were higher in patients who experienced recurrence in the follow‐up period compared with patients without recurrence (P = 0.008 and 0.007 for MN and QIAGEN kits respectively). Significant associations were also found between cf DNA concentrations and tumor stage (P = 0.005 and 0.02 for MN and QIAGEN kits respectively). Notably, cf DNA concentration was higher in metastatic tumors compared with non‐metastatic tumors in association with number of involved organs. Based on the AUC values, both kits could differentiate metastatic cancers from non‐metastatic ones with accuracy of 98%.Conclusions: The current study highlights the accuracy of cf DNA concentrations for prediction of disease course in lung cancer patients.Keywords
Funding Information
- Tehran University of Medical Sciences and Health Services (TUMS)
This publication has 12 references indexed in Scilit:
- Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancerOncotarget, 2016
- Circulating free DNA concentration is an independent prognostic biomarker in lung cancerEuropean Respiratory Journal, 2015
- Association ofEGFRL858R Mutation in Circulating Free DNA With Survival in the EURTAC TrialJAMA Oncology, 2015
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human MalignanciesScience Translational Medicine, 2014
- Clinical and Organizational Factors in the Initial Evaluation of Patients With Lung CancerChest, 2013
- Quantitative analysis of cell-free DNA in the plasma of gastric cancer patientsOncology Letters, 2012
- Cell-free nucleic acids as biomarkers in cancer patientsNature Reviews Cancer, 2011
- Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: A meta-analysisLung Cancer, 2010
- Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival.2002
- Toxicity and response criteria of the Eastern Cooperative Oncology GroupAmerican Journal of Clinical Oncology, 1982